| Trial ID: | L5323 |
| Source ID: | NCT01751399
|
| Associated Drug: |
Ly2605541
|
| Title: |
A Single Dose Study of LY2605541 in Participants With Liver Impairment
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01751399/results
|
| Conditions: |
Healthy Volunteers|Hepatic Insufficiency|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY2605541
|
| Outcome Measures: |
Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541, Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose|Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541, Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose |
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
35
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-12
|
| Completion Date: |
2013-09
|
| Results First Posted: |
2018-10-19
|
| Last Update Posted: |
2018-10-19
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, 81241, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Balatonfured, 8230, Hungary
|
| URL: |
https://clinicaltrials.gov/show/NCT01751399
|
